Connect with us

Media OutReach

Rhenus Group expands Management Board to drive transformation and growth

Published

on

  • Rhenus Group expands Management Board from four to seven members to reflect the Group’s significant transformation and growth ambition, elevating crucial roles to the highest level of decision-taking
  • Dr. Joana Bätz appointed member of the Rhenus Group Management Board with responsibility for the Group functions for Human Resources, Sustainability and Compliance
  • Jan Harnisch appointed member of the Rhenus Group Management Board for the Air & Ocean Division
  • Dr. Marcus Ewig appointed member of the Rhenus Group Management Board for the Automotive Division and Group Procurement, Health & Safety and Quality Management

SINGAPORE – Media OutReach Newswire – 28 March 2025 – Effective 1 April 2025, the Rhenus Group has appointed three experienced leaders from within the company to the Management Board. Dr. Joana Bätz will be representing the Group functions for Human Resources, Sustainability and Compliance, Jan Harnisch for Air & Ocean and Dr. Marcus Ewig for Automotive as well as the Group functions Procurement, Health & Safety and Quality Management. The expansion of the Management Board reflects the company’s transformation into a leading global logistics company, lifting crucial roles to the highest level of decision-taking and reinforcing the Group’s commitment to future growth.

Over the past three decades, Rhenus has evolved from a mid-sized German logistics company into the world’s largest family-owned logistics provider, offering resilient and integrated supply chain solutions tailored to the rapidly changing needs of diverse industries. To navigate the complexities of the global logistics market and drive sustainable transformation, Rhenus has recognized the need for enhanced leadership and strategic guidance at the highest level. The expansion of the Management Board is a key step in this direction.

“We are delighted to welcome three accomplished leaders in their respective areas of responsibility to the Management Board,” says Dr. Marco Schröter, Chairman of the Supervisory Board Rhenus Group. “These appointments demonstrate our commitment to leveraging our own talent and the deep expertise within Rhenus Group. Their combined experience will be invaluable as we navigate the evolving logistics landscape and pursue our ambitious growth path.”

“With the expansion of our Management Board we are reinforcing our people-centered approach and our commitment to future-proofing our company for generations to come. In addition, we are setting an important focus on strengthening all our divisions on a global level: in times of geopolitical volatility and rapidly changing market environments, we are ensuring that we can provide even more resilient, tailor-made logistics solutions for our customers and meet the specific needs of each industry even better,” adds Tobias Bartz, CEO Rhenus Group. “I have had the pleasure of working alongside these great colleagues for many years. Their operational expertise, strategic mindset, deep industry knowledge and their alignment with the unique Rhenus family values will be strong assets to the board. I’m delighted to welcome them and wish them every success in their new roles.”

New Board Member Appointments

With the appointment of Dr. Joana Bätz, Rhenus is giving top priority to its employees, the driving force behind the company’s success. Overseeing the Group functions for Human Resources, Compliance and Sustainability, she holds a key role in shaping the Group’s long-term strategy. Joana Bätz brings almost two decades of experience in the logistics sector, seven years of those spent with the Rhenus Group. She rapidly advanced into global leadership roles, before she was appointed Group CHRO in 2022. In this role, she implemented a professionalized Group-wide HR organization, significantly drove the company’s cultural change and brought people management to the next level by introducing HR technology solutions and launching a global employer brand. She received her doctorate from the Johann Wolfgang Goethe University, Frankfurt (Main), with a focus on Human Resources and Organizational Development.

Air & Ocean is now represented on the Board by its global CEO, Jan Harnisch, who has been with Rhenus since 2012. He has held leadership roles within the Air & Ocean Division at both global and regional levels, including Global COO since 2020 and Global CEO since 2022. Jan played a pivotal role in the division’s expansion into new international markets while driving operational excellence, digital transformation, and strategic growth. His focus is on scaling Rhenus Air & Ocean’s position as a global top player in freight forwarding by accelerating its international footprint, increasing agility, and advancing customer-centric logistics solutions that drive long-term value.

Dr. Marcus Ewig has been elevated to the Management Board from his role as CEO of Rhenus Automotive, a position he has held since 2017. His key achievements include leading the international expansion of Rhenus Automotive into China and the US, establishing a joint venture for battery lifecycle management, and continuously driving the divisions growth and success. Marcus Ewig can tap into his vast experience in the automotive sector, having held various leadership positions at Porsche. In addition to Automotive, he will also be responsible for the Group functions Procurement, Health & Safety and Quality Management. He earned his doctorate in business informatics at the University of Leipzig.

Moving forward, the Management Board of the Rhenus Group will have seven members: Tobias Bartz (CEO & Chairman), Gilles Delarue, Dr. Stephan Peters, Andreas Stöckli, Dr. Joana Bätz, Jan Harnisch, and Dr. Marcus Ewig, each contributing their unique expertise to drive the company’s continued success.
Hashtag: #Rhenus

The issuer is solely responsible for the content of this announcement.

About Rhenus Group

The Rhenus Group is one of the leading logistics specialists with global business operations and annual turnover amounting to EUR 7.5 billion. 40,000 employees work at 1,320 business sites in more than 70 countries and develop innovative solutions along the complete supply chain. Whether providing transport, warehousing, customs clearance or value-added services, the family-owned business pools its operations in various business units where the needs of customers are the major focus at all times.

Advertisement

Media OutReach

St. George’s University Prepares Future South Korean Physicians for the Growing Global Cancer Care Challenge

Published

on

SEOUL, SOUTH KOREA – Media OutReach Newswire – 4 February 2026 – Rising global cancer incidence is straining healthcare systems, which already face workforce shortages. In East Asia, the number of trained physicians in cancer care, spanning diagnosis, treatment coordination, and long-term management—has not met the increasing demand. According to the Global Cancer Observatory, South Korea reported over 230,000 new cancer cases and more than 97,000 fatalities in 2022. A recent original academic research by Myongji College and The Catholic University of Korea warned that simply increasing medical school enrollments alone does not fix shortages in key specialties and underserved regions where medical demand is rising fastest.

Source: St. George’s University

Recognizing the importance of addressing workforce shortage in South Korea, St. George’s University (SGU) School of Medicine in Grenada, West Indies, highlights how its medical education approach supports the development of clinical competencies relevant to cancer care across healthcare settings.

These challenges reflect broader global trends, where cancer care increasingly depends on multidisciplinary teams rather than specialty expansion alone. SGU’s curriculum is designed to build a strong foundation in clinical diagnosis, patient communication and multidisciplinary care, which are essential skills for effective oncology and cancer-related care. Through anatomy labs, simulation-based learning, and integrated digital tools, students develop foundational clinical skills in structured, supervised environments designed to reflect real-world medical practice.

The curriculum also integrates traditional cadaveric dissection with modern 3D anatomical modeling. This blend helps students visualize the human body in a holistic way while reinforcing knowledge through their hands-on interaction. SGU’s simulation lab also enables medical students to have their first direct interaction with ill patients in a safe, simulated learning environment.

On top of core medical training, SGU offers early exposure to prevention, diagnosis and patient-centered care to prepare graduates to tackle complex health issues. SGU has developed long-standing relationships with more than 75 established hospitals and clinical centers in the US and UK. These clinical placements provide exposure to diverse patient populations and care environments, including settings where cancer diagnosis and management are part of routine clinical practice.

South Korean SGU alumni are contributing to healthcare systems through roles that intersect with cancer diagnosis, treatment coordination, and long-term patient care. For example, Dr. Julia Hweyryoung Cho, MD 2022 is practicing internal medicine, which plays a crucial role in cancer care. Internal medicine physicians are often involved in the initial diagnosis of cancer, managing complex medical conditions that may arise during treatment and providing long-term comprehensive care and survivorship planning for patients with a history of cancer.

In observance of World Cancer Day 2026, SGU encourages all medical professionals and organizations to collaboratively address global cancer care challenges. This includes recognizing and meeting the cancer healthcare needs of individuals and communities in South Korea.

For more information on the programs and tracks available through SGU School of Medicine, visit SGU’s website.Hashtag: #St.George’sUniversity

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Finalists and Semifinalists for $1 Million Seeding The Future Global Food System Challenge Announced

Published

on

BONN, GERMANY – Newsaktuell – 3 February 2026 – The Seed Grant Finalists and Growth Grant and Seeding the Future Grand Prize Semifinalists of the 5th annual Seeding The Future Global Food System Challenge (GFSC) have been announced, marking a key milestone in the USD 1 million global Challenge supporting impactful and innovative solutions to transform food systems.

Created and funded by Seeding The Future Foundation and, for the first time, hosted by Welthungerhilfe (WHH), the Challenge attracted a record 1,600+ applications from innovator teams in 112 countries, underscoring growing global momentum for food systems transformation.

Following a multi-stage, rigorous international review process, 36 teams have advanced across three award levels. These include 16 Seed Grant Finalists (competing for 8 awards of USD 25,000), 12 Growth Grant Semifinalists (competing for 3 awards of USD 100,000), and 8 Seeding The Future Grand Prize Semifinalists (competing for 2 awards of USD 250,000).

“Hosting the GFSC reflects Welthungerhilfe’s commitment to accelerating bold, scalable innovations where they are needed most. This year’s diversity of solutions underscores the complexity of food system challenges and the creativity of innovators worldwide.” said Jan Kever, Head of Innovation at Welthungerhilfe

The submitted innovations span diverse themes and approaches, including climate-smart production, nutrient-dense foods, food loss reduction, and inclusive market models, reflecting the complexity and interconnected nature of today’s food systems challenges.

“The Seeding The Future Global Food System Challenge exists to catalyze impactful, bold, and scalable innovations that advance food systems transformation. We are excited to work alongside Welthungerhilfe as a trusted partner and host of the Challenge and are encouraged by the quality and diversity of innovations emerging from this first year of collaboration.” said Bernhard van Lengerich, Founder and CEO of Seeding The Future Foundation

While the number of awards is limited, all semifinalists and finalist applicants plus all applicants with any prior recognition of other innovation competitions can join the STF Global Food System Innovation Database and Network—currently in beta testing with the Food and Agriculture Organization of the United Nations—vastly expanding their visibility and reach across a global audience.

List of 2025 GFSC Seed Grant Finalists, Growth Grant and Seeding The Future Grand Prize Semifinalists

Find details here: welthungerhilfe.org/gfsc-finalists

Seeding The Future Grand Prize Semi-Finalists

Growth Grant Semi-Finalists

Seed Grant Finalists

Hashtag: #TheFutureGlobalFoodSystemChallenge

The issuer is solely responsible for the content of this announcement.

About Seeding The Future Foundation

STF is a private nonprofit dedicated to ensuring equitable access to safe, nutritious, affordable, and trusted food. It supports innovations that transform food systems and benefit both people and planet. More at .

About Welthungerhilfe
WHH is one of Germany’s largest private aid organizations, striving for a world without hunger since 1962. More at:

Continue Reading

Media OutReach

PolyU develops novel antibody targeting fat cell protein, offering new approach to treating metabolism-related liver cancer

Published

on

HONG KONG SAR – Media OutReach Newswire – 3 February 2026 – Liver cancer is one of the three deadliest cancers worldwide, and metabolic dysfunction-related cases have become increasingly common in recent years. A research team from The Hong Kong Polytechnic University (PolyU) has identified a protein secreted by fat cells that promotes cancer growth and has successfully developed a novel antibody that neutralises this protein, marking a significant breakthrough in impeding the progression of liver cancer. The research findings have been published in the Journal of Clinical Investigation.

Prof. Terence Lee, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, and his research team have developed a novel antibody targeting the adipocyte-derived protein FABP4, offering a new approach to treating metabolism-related liver cancer.

Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, currently affects around a quarter of the global population and is an important risk factor for liver cancer. In affected individuals, fat cells induce insulin resistance and chronic inflammation, leading to excessive fat accumulation in the liver. This ultimately impairs liver function and may progress to liver cancer. Treatment options for MASLD-induced liver cancer remain limited and the effectiveness of current immunotherapies is suboptimal.

A breakthrough study led by Prof. Terence LEE, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, and his research team has revealed that an adipocyte-derived protein, known as fatty acid-binding protein 4 (FABP4) is a key driver that accelerates tumour growth. Through mass spectrometry, the team confirmed that patients with MASLD-induced liver cancer had markedly elevated FABP4 levels in their serum. Further investigations showed that FABP4 activates a series of pro-proliferative signalling pathways within cells, causing cancer cells to multiply and grow more rapidly.

Prof. Lee’s team has successfully developed a monoclonal antibody that neutralises FABP4. This antibody not only inhibits the growth and proliferation of FABP4-driven cancer stem cells, but also enhances the ability of immune cells to combat cancer.

Prof. Lee said, “This neutralising antibody against FABP4 demonstrates significant potential in inhibiting tumour growth and activating immune cells, providing a complementary approach to current immunotherapy strategies. Our findings highlight that targeting adipocyte-derived FABP4 holds promise for treating MASLD-induced liver cancer.”

Prof. Lee added that gaining deeper insights into how adipocyte-derived FABP4 affects liver cancer cells helps to explicate the disease mechanisms of liver cancer, particularly in obese individuals. Intervening in the relevant signalling pathways could provide effective methods to combat this aggressive malignancy.

Prof. Lee believes that, as this adipocyte-targeted immunotherapy continues to mature, it will bring more treatment options to MASLD patients. He remarked, “If its efficacy can be proven in clinical trials, it could offer new hope to many affected individuals.”

The research is supported by the Innovation and Technology Fund of the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China. PolyU has filed a non-provisional patent for the developed antibody and is continuing to optimise its binding affinity to facilitate future clinical applications.
Hashtag: #PolyU #FattyLiver #Cancer #LiverCancer #理大 #香港理工大学 #肝癌 #癌症 #脂肪肝

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending